Navigation Links
Champions Oncology Reports Fiscal 2012 First Quarter Financial Results
Date:9/13/2011

ians and patients looking for information help guide the development of personalized treatment plans, and Translational Oncology Solutions ("TOS") in which pharmaceutical and biotech companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs and increasing the adoption of existing drugs. The Company's Tumorgraft™ Technology Platform consists of processes, physical tumors and information that we use to personalize the development and use of oncology drugs.  The Company is building its Tumorgraft™ Technology Platform through the procurement, development and characterization of numerous Tumorgrafts™ within each of several cancer types.  Tumorgrafts™ are procured through agreements with a number of institutions in the U.S. and overseas as well as through its POS business.  The Tumorgrafts™ are developed and tested through agreement with a United States-based preclinical facility.

The Company provides POS to oncologists by establishing and administering expert tumor panels for their patients to analyze medical records and test results, to assist in understanding conventional and experimental options and to identify and arrange for testing, analysis and study of the patients' cancer tissues, as appropriate.  Additionally, the Company offers Personalized Tumorgraft™ development, drug studies and genome sequencing as part of its POS whereby physicians can evaluate the effects of cancer drugs on their patients' tumorgrafts and understand the genetic make-up of their patient's tumor enabling them to better select treatment regimens that may be efficacious to the patient.

This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties.  Champions Oncology generally uses words such as "believe," "may," "could," "will," "inten
'/>"/>

SOURCE Champions Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Five Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California
2. Champions Biotechnology Exercises Option to License Proprietary Compound Based on Successful Tumorgraft™ Test Results
3. Champions CFO Resigns
4. Champions Biotechnology Awarded $1.46 million in Grants
5. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
6. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
7. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
8. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
9. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
10. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
11. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... DIEGO , April 17, 2015  Trovagene, ... diagnostics, announced today that clinical data presented at ... that its urine-based Precision Cancer Monitoring ℠ ... and monitoring of EGFR T790M mutations ... Detection of EGFR T790M Mutation in Urinary ...
(Date:4/17/2015)... DUBLIN , Apr. 17, 2015 Research and ... addition of the "Medical Oxygen Systems - Global ... This report analyzes the worldwide markets for Medical ... Oxygen Concentrators, Liquid Oxygen Systems, Oxygen Cylinders & Regulators, ... analytics for the US, Canada , ...
(Date:4/17/2015)... -- Today, the Pharmaceutical Research and Manufacturers of ... companies as "We Work For Health Champions" for ... service. Established in 2009, the We ... the biopharmaceutical industry to honor employees who have ... also shown an outstanding commitment to their communities ...
Breaking Medicine Technology:Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4Medical Oxygen Systems - 2015 Global Strategic Business Report Featuring Leading Players, Caire, Invacare & Philips Respironics 2PhRMA Applauds 2015 We Work For Health Champion Award Winners 2PhRMA Applauds 2015 We Work For Health Champion Award Winners 3
... Water Street Healthcare Partners , a strategic private equity ... it has acquired MarketLab, Inc.  Water Street,s ... specialty healthcare distribution sector.  The acquisition expands Water Street,s ... life sciences, medical devices and services to 13. ...
... -- Dehaier Medical Systems Ltd. (NASDAQ: ... in the development, assembly, marketing and sale of medical ... that it was granted three new patents by State ... ("SIPO"). The patent awards were related to the design ...
Cached Medicine Technology:Water Street Healthcare Partners Acquires MarketLab, Inc. 2Water Street Healthcare Partners Acquires MarketLab, Inc. 3Dehaier Strengthens Intellectual Property Portfolio 2Dehaier Strengthens Intellectual Property Portfolio 3
(Date:4/18/2015)... Omaha, NE (PRWEB) April 18, 2015 ... leader in healthcare staffing, including physical therapy jobs, ... exhibitor at the South Carolina Physical Therapy Association ... at the Kroc Center in Greenville, SC. ... networking opportunities, and exhibits with products and services. ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 PHOENIX, ARIZONA ... County, along with 11 other secure destruction professionals across ... Destruction Specialists (CSDS). He will now display “CSDS” as ... were offered before the National Association of Information Destruction ... and another Grapevine, Texas. Of the 20 people who ...
(Date:4/17/2015)... (PRWEB) April 18, 2015 Heritage Woods ... begin its Supportive Living Week Celebration on April 20 ... having a healthy mind, body and soul. , The ... McLeansboro, Illinois, serves older adults of all incomes, including ... their independence. , Supportive Living Week is observed every ...
(Date:4/17/2015)... Rosetta Radiology is proud to now offer ... of diagnostic imaging services. This solidifies them as a ... East Side of Manhattan. , The new imaging equipment ... of PET-CT, combined with Rosetta’s state of the art ... with patients through several stages of the cancer care ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Riviera ... Dr. Kevin Sadati of the Gallery of Cosmetic ... County’s top beauty experts. The publication focused on ... facial stem cell fat grafting, eyelid surgery, laser resurfacing ... facial plastic surgery has resulted in thousands of ...
Breaking Medicine News(10 mins):Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the South Carolina Physical Therapy Association Annual Conference 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 3Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 2Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 3
... (Nasdaq: AMGN ) will present at the ... May 18, 2009 at the InterContinental, Boston, Mass., beginning ... Executive Officer Kevin Sharer will present. Live audio of ... can be accessed from Amgen,s Web site, www.amgen.com ...
... risk by 35%, study finds , , WEDNESDAY, May ... medications may ease the symptoms of bronchiolitis -- a ... research suggests this treatment may reduce the risk of ... wheezing sooner and get babies back to normal feeding ...
... Plan Yields Positive ResultsCLEVELAND, May 13 DATATRAK International, ... services company focused on global eClinical solutions for the ... the first quarter of 2009. Revenue for the first ... to $2,088,000 in the same period of 2008. Gross ...
... VIEW, Calif., May 13 MAP Pharmaceuticals, Inc. (Nasdaq: ... at the Deutsche Bank Securities 34th Annual Health ... (ET) in Boston, MA.A live webcast of the presentation will ... website at http://www.mappharma.com . A replay will also be ...
... from a study of managed-care cancer patients receiving chemotherapy ... the cumulative ESA cost with Epoetin alfa (EPO) was ... The analysis, published in the Spring issue of ... by Centocor Ortho Biotech Services, LLC. The retrospective ...
... a lawsuit against the U.S. Patent and Trademark Office and Myriad ... as BRCA1 and BRCA2, which are indicators for hereditary predisposition to ... ... May 13, 2009 -- The College of American Pathologists today joined ...
Cached Medicine News:Health News:Combo Treatment Eases Wheezing in Babies 2Health News:Combo Treatment Eases Wheezing in Babies 3Health News:DATATRAK International, Inc. Announces First Quarter Results for 2009 2Health News:DATATRAK International, Inc. Announces First Quarter Results for 2009 3Health News:DATATRAK International, Inc. Announces First Quarter Results for 2009 4Health News:DATATRAK International, Inc. Announces First Quarter Results for 2009 5Health News:DATATRAK International, Inc. Announces First Quarter Results for 2009 6Health News:Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients With Epoetin Alfa Associated With Lower Drug Cost Than Darbepoetin Alfa 2Health News:Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients With Epoetin Alfa Associated With Lower Drug Cost Than Darbepoetin Alfa 3Health News:Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients With Epoetin Alfa Associated With Lower Drug Cost Than Darbepoetin Alfa 4Health News:Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients With Epoetin Alfa Associated With Lower Drug Cost Than Darbepoetin Alfa 5Health News:Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients With Epoetin Alfa Associated With Lower Drug Cost Than Darbepoetin Alfa 6Health News:CAP Joins Landmark Lawsuit Challenging Legality of Myriad Genetics Gene Patents 2
... Choose from a complete ... and AC halogen light ... cool illumination. A solid-state ... intensity, and our exclusive ...
Inquire...
... inverted microscope technology that offers you much more ... in this category. You will be impressed by ... been designed to make lab work as easy ... efficiency of your workflow. Your advantage: more time ...
... represents the most advanced motorized inverted microscope ... and optical design provides 9 access ports ... to four ports can have simultaneous access ... motorized Z-axis drive, 6-position nosepiece and light ...
Medicine Products: